Select one:

☐ NEXLIZET® (bempedoic acid/ezetimibe) 180mg/10mg tablets

☐ NEXLETOL® (bempedoic acid) 180mg tablets

Prescriber: _____

Patient: _____

Patient D.O.B.: _____

For appropriate primary prevention and secondary prevention patients consider including the following information on prior authorizations (PA)

Please include all 3 criteria steps on prior authorization

1. Indicated Diagnosis Codes:

Primary Prevention Patients:

- ☐ E78.2: Mixed hyperlipidemia
- ☐ E78.5: Hyperlipidemia
- ☐ E78.01 Familial hypercholesterolemia
- ☐ E78.49: Other hyperlipidemia

If treating hyperlipidemia, payers may require one of the following:

- ☐ Diabetes

OR

- ☐ CAC > 300 or 400

OR

- ☐ ASCVD Risk Score > 20%

OR

Secondary Prevention Patients:

- ☐ I24.9: ACS
- ☐ I21.____: MI
- ☐ I20.____: Angina
- ☐ G45.9: TIA
- ☐ I73.9: PAD
- ☐ I70.8: Atherosclerosis/ Revascularization
- ☐ I63.____: Stroke
- ☐ I25.10: CAD

2. Treatment History:

Statin History is required

Current Statin & Dose: _____

Past Statin & Dose: _____

May be required: Ezetimibe: ☐ YES ☐ NO

3. Recent LDL–C Level: _____

INDICATION

NEXLIZET and NEXLETOL are indicated:The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with established cardiovascular disease (CVD), or at high risk for a CVD event but without established CVD.

IMPORTANT SAFETY INFORMATION

NEXLIZET and NEXLETOL are contraindicated in patients with a prior hypersensitivity to bempedoic acid or ezetimibe or any of the excipients. Serious hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported.

Please see additional important safety information on next page

INDICATION

As an adjunct to diet: NEXLIZET® (bempedoic acid/ezetimibe), alone or in combination with other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. NEXLETOL® (bempedoic acid), in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH.

IMPORTANT SAFETY INFORMATION

Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.

Tendon Rupture: Bempedoic acid, a component of NEXLIZET and NEXLETOL, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture.

The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid, a component of NEXLIZET and NEXLETOL, in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.

Adverse reactions reported in ≥2% of patients treated with ezetimibe (a component of NEXLIZET) and at an incidence greater than placebo in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza.

In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence ≥3% and greater than placebo) observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, were urinary tract infection, nasopharyngitis, and constipation.

The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.

Concomitant use of NEXLIZET or NEXLETOL with greater than 20 mg of simvastatin or 40 mg of pravastatin should be avoided due to the potential for increased risk of simvastatin- or pravastatin-related myopathy.

Discontinue NEXLIZET or NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLIZET or NEXLETOL.

Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

References: 1. NEXLIZET. Prescribing information. Esperion Therapeutics, Inc. **2.** NEXLETOL. Prescribing information. Esperion Therapeutics, Inc.

Please see full prescribing information here: NEXLETOL and for NEXLIZET

To learn more, visit NEXLIZETHCP.com

ESPERION®